Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Contraception

• Publication date

  1993-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0010-7824(93)90141-SPMID 8222650
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical experience and pharmacological effects of an oral contraceptive containing 20 micrograms oestrogen.

  1992cited by this paper
• A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.

  1992cited by this paper
• The metabolic impact of oral contraceptives.

  1992cited by this paper
• Effects of low and high dose oral contraceptives on blood coagulation and thrombogenesis induced by vascular subendothelium exposed to flowing human blood.

  1991cited by this paper
• A comparative study on the effects of a monophasic pill containing desogestrel plus 20 micrograms ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors.

  1991cited by this paper
• Desogestrel and Gestodene in Oral Contraceptives: 12 Months’ Assessment of Carbohydrate and Lipoprotein Metabolism

  1991cited by this paper
• Effects of three combined oral contraceptive preparations containing desogestrel plus ethinyl estradiol on lipid metabolism in comparison with two levonorgestrel preparations.

  1990cited by this paper
• The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.

  1990cited by this paper
• Comparison of the lipoprotein and hemostatic changes after a triphasic and a monophasic low dose oral contraceptive in premenopausal middle-aged women.

  1990cited by this paper
• Some aspects of the relationship between oral contraceptives, lipid abnormalities, and cardiovascular disease.

  1990cited by this paper
• Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives.

  1988cited by this paper
• A comparison of the effects of two triphasic oral contraceptives on haemostasis

  1988cited by this paper
• Comparative Trial of the Effects on Glucose Tolerance and Lipoprotein Metabolism of two New Oral Contraceptives Containing Gestoden and Desogestrel

  1988cited by this paper
• Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins.

  1987cited by this paper
• Clinical and metabolic study of a new pill containing 20 mcg ethinylestradiol plus 0.150 mg desogestrel.

  1987cited by this paper
• A new low-dose estrogen oral contraceptive combination: effect on endocrine parameters and lipid status.

  1987cited by this paper
• Effect of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism.

  1987cited by this paper
• Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel.

  1986cited by this paper
• Serum lipids and proteins during treatment with a new oral contraceptive combination containing desogestrel.

  1983cited by this paper
• Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins.

  1978cited by this paper
• Methodologic problems in plasma renin activity measurements.

  1976cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper

• A New Pharmacodynamic Test to Evaluate Effects of Oral Contraceptives on Coagulation

  2021cites this paper
• Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk

  2020cites this paper
• [Hypertension and contraception].

  2019cites this paper
• Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis

  2016cites this paper
• Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus.

  2014cites this paper
• 20 µg versus >20 µg estrogen combined oral contraceptives for contraception.

  2013cites this paper
• Effect of a Combined Oral Contraceptive Containing 30 mg Ethinylestradiol and 75 mg Gestodene on Haemostatic Mechanisms in a Group of Albanian Women

  2013cites this paper
• Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus.

  2012cites this paper
• Treatment options for females with hypogonadotropic hypogonadism and thromboembolism

  2011cites this paper
• Effect of Injectable and Oral Contraceptives on Glucose and Insulin Levels

  2011cites this paper
• Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol

  2011cites this paper
• 20 µg versus >20 µg estrogen combined oral contraceptives for contraception.

  2011cites this paper
• Low-dose oral contraceptives in adolescents: how low can you go?

  2010cites this paper
• Twenty or thirty microgram ethinyloestradiol in an oral contraceptive: Does it make a difference in the mind and the daily practise of gynaecologists and general practitioners?

  2009cites this paper
• The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters.

  2009cites this paper
• Prevention of venous thromboembolism.

  2009cites this paper
• Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus.

  2009cites this paper
• Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study.

  2008cites this paper
• 20 microg versus >20 microg estrogen combined oral contraceptives for contraception.

  2008cites this paper
• Tolérance biologique et clinique. du Nomégestrol acétate, administré seul puis associé en séquentiel inversé au 17 ß estradiol cutané, chez des femmes à risque présentant une dyslipoprotéinémie de type IIa

  2008cites this paper
• Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus.

  2007cites this paper
• Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study.

  2007cites this paper
• 20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception.

  2005cites this paper
• Twenty micrograms vs. >20 microg estrogen oral contraceptives for contraception: systematic review of randomized controlled trials.

  2005cites this paper
• Sex hormone--binding globulin--a surrogate marker for the prothrombotic effects of combined oral contraceptives.

  2004cites this paper
• Sex hormoneebinding globulindA surrogate marker for the prothrombotic effects of combined oral contraceptives

  2004cites this paper
• A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties.

  2003cites this paper
• Plasma cortisol levels and workers exposed to urban pollutants.

  2003cites this paper
• The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study.

  2003cites this paper
• Contraceptive Efficacy and Tolerability of Chlormadinone Acetate 2mg/ Ethinylestradiol 0.03mg (Belara®)

  2002cites this paper
• Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence.

  2001cites this paper
• The emerging use of the 20-μg oral contraceptive

  2001cites this paper
• Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women.

  2001cites this paper
• [Which contraception to choose for the diabetic woman?].

  2001cites this paper
• The emerging use of the 20-microg oral contraceptive.

  2001cites this paper
• Oral Contraceptives, Hormone Replacement Therapy and Haemostasis

  2000cites this paper
• A Randomized Cross-over Study on the Effects of Levonorgestrel- and Desogestrel-containing Oral Contraceptives on the Anticoagulant Pathways

  2000cites this paper
• Efeitos do contraceptivo oral contendo 20 µg de etinilestradiol e 150 µg de desogestrel sobre os sistemas de coagulação e fibrinólise

  2000cites this paper
• Cardiovascular disease: pathogenesis, epidemiology, and risk among users of oral contraceptives who smoke.

  1999cites this paper
• A clinician's response to the oral contraceptive thrombosis controversy.

  1999cites this paper
• Biological coagulation findings in third-generation oral contraceptives.

  1999cites this paper
• The effects of a low-dose monophasic preparation of levonorgestrel and ethinyl estradiol on coagulation and other hemostatic factors.

  1999cites this paper
• A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel.

  1999cites this paper
• Hemostatic Effects of Oral Contraceptives in Women who Developed Deep-vein Thrombosis while Using Oral Contraceptives

  1998cites this paper
• [Biological and clinical safety of nomegestrol acetate administered alone then associated in inverse sequence with transdermal 17 beta estradiol, in women at risk of dyslipoproteinemia type IIa].

  1998cites this paper
• Oral contraceptives and arterial and venous thrombosis: a clinician's formulation.

  1998cites this paper
• [Contraceptive use in female transplant recipients].

  1998cites this paper
• Developments in contraception: a comprehensive review of Desogen (desogestrel and ethinyl estradiol).

  1998cites this paper
• 9 Haemostatic changes and the oral contraceptive pill

  1997cites this paper
• Haemostatic changes and the oral contraceptive pill.

  1997cites this paper
• Modulation of Glomerular ECTO-ADPase Expression by Oestradiol

  1997cites this paper
• Effect of Oral Contraceptives on Haemostasis Variables

  1997cites this paper
• The estrogen component of OCs: cardiovascular benefits and risks.

  1997cites this paper
• Prevention of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence).

  1997cites this paper
• Estrogènes

  1997cites this paper
• The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives

  1996cites this paper
• Ethinylestradiol 20 versus 30 micrograms combined with 150 micrograms desogestrel: a large comparative study of the effects of two low-dose oral contraceptives on the hemostatic system.

  1996cites this paper
• Estrogen dose and progestogen type: Their effect on hemostatic changes in oral contraceptive users

  1996cites this paper
• The effects of two phasic oral contraceptives on hemostasis and platelet function

  1995cites this paper
• Classification and comparison of oral contraceptives containing new generation progestogens.

  1995cites this paper
• Prevention of Venous Thromboembolism

  1994cites this paper